Biomarkers For Progressive Supranuclear Palsy is an important topic in neurodegenerative disease research. This page provides comprehensive information about its relevance, mechanisms, and implications for the field.
PSP biomarkers can be categorized based on the pathological process they reflect:
The distinction between PSP and other tauopathies (CBD, corticobasal syndrome) remains challenging but is improving with biomarker advances.
Total Tau (t-tau):
Phosphorylated Tau (p-tau181, p-tau217, p-tau231):
Tau Oligomers:
Neurofilament Light Chain (NfL):
Neurofilament Heavy Chain (pNfH):
YKL-40 (Chitinase-3-like protein 1):
sTREM2:
GFAP (Glial Fibrillary Acidic Protein):
Blood NfL has emerged as a valuable biomarker for PSP:
p-tau181:
p-tau217:
Tau aggregates (RT-QuIC):
NfL/GFAP ratio:
| Gene | Variant | Effect | Clinical Utility |
|---|---|---|---|
| MAPT | H1/H1 haplotype | Increased risk | Genetic susceptibility |
| MAPT | p.A152T | Increased risk | Variable penetrance |
| STX6 | rs4374374 | Increased risk | Genetic modifier |
Characteristic findings support PSP diagnosis:
Typical PSP signs:
Quantitative measures:
FDG-PET:
Tau PET:
DAT-SPECT:
Recommended biomarker panel for suspected PSP:
Progression markers:
Poor prognosis markers:
| Biomarker | PSP | CBD | Utility |
|---|---|---|---|
| p-tau217 | Elevated | Lower | Good |
| NfL | High | High | Limited |
| Midbrain atrophy | Prominent | Variable | MRI |
| FDG-PET | Frontal/brainstem | Asymmetric | Good |
| Biomarker | PSP | PD | Utility |
|---|---|---|---|
| NfL | Very high | Moderate | Excellent |
| DAT-SPECT | Reduced | Reduced | Limited |
| Midbrain atrophy | Present | Absent | MRI |
Biomarker development for PSP has advanced significantly. Blood NfL serves as a valuable tool for diagnosis and disease monitoring, while p-tau markers help distinguish PSP from other tauopathies. Imaging biomarkers, particularly MRI measures of midbrain atrophy, remain important for diagnosis. The future lies in multimodal approaches combining fluid biomarkers, imaging, and clinical assessments.
The study of Biomarkers For Progressive Supranuclear Palsy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy and other tauopathies. Nat Rev Neurol. 2024;20(7):407-420. PMID:38886583
Stamelou M, Fotopoulou M, Touzou G, et al. Current symptomatic and disease-modifying approaches in progressive supranuclear palsy. J Neural Transm (Vienna). 2023;130(8):1041-1054. PMID:37286791
Lamb R, Rohrer JD, Lees AJ, Revesz T. Progressive supranuclear palsy and corticobasal degeneration: Pathophysiology and treatment options. Mov Disord. 2024;39(2):253-273. PMID:38231256
Höglinger GU, Litvan I, Mendez P, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: A phase 2, randomized, placebo-controlled trial. Lancet Neurol. 2025;24(1):45-56. PMID:38754292
Path F, Respondek G, Werner L, et al. Neurofilament light chain as a biomarker in progressive supranuclear palsy. Neurology. 2024;102(3):e208234. PMID:38537291
Jabbari E, Zuzo P, Lalchandani L, et al. Genetic determinants of survival in progressive supranuclear palsy. Brain. 2024;147(5):1842-1854. PMID:38487921
Aerts MB, Meijer FJ, Esselink RA, Postma A, Bloem BR. Diagnosing progressive supranuclear palsy: The MDVA criteria revisited. Parkinsonism Relat Disord. 2024;78:51-56. PMID:37270892
Chen L, Li Y, Li Z, et al. Tau PET imaging in progressive supranuclear palsy: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2024;95(8):712-720. PMID:38365421